Drug Trial Radar · NCT01126970
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
Last checked: Nov 20, 2026Latest source record: May 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
486
Actual
Start
Apr 2010
Primary completion
Jan 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit (S-2367), velneperit (S-2367) tert-butyl OH, and velneperit (S-2367) tert-butyl OH-O glucuronide following 400 mg of velneperit (S-2367) three times per day and 120 mg of orlistat, either combined or separate.
Conditions
- Obesity
Interventions
Velneperit 400 mgDrug
Velneperit 400 mg q.d.
Orlistat 120 mgDrug
Orlistat 120 mg t.i.d
Orlistat PlaceboDrug
Orlistat Placebo t.i.d.
Velneperit PlaceboDrug
Velneperit Placebo q.d
Reduced Calorie DietOther
Reduced calorie diet
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint was the change from baseline in body weight (kg) over the 168-day (24-week) double-blind treatment period, where baseline body weight was defined as the last measurement prior to randomizationTime frame: 168 days (24 weeks)
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Santa Rosa, California
Site not named
Waterbury, Connecticut
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Ocala, Florida
Site not named
Ponte Vedra, Florida
Site not named
Augusta, Georgia
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Milford, Massachusetts
Site not named
North Dartmouth, Massachusetts
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Albuquerque, New Mexico
Site not named
Manlius, New York
Site not named
Rochester, New York
Site not named
Cary, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Greenville, South Carolina
Site not named
Nashville, Tennessee
Site not named
New Braunfels, Texas
Site not named
Renton, Washington
Site not named
Wauwatosa, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.